Tim-3 inhibits T helper type 1–mediated auto- and alloimmune responses and promotes immunological tolerance

By A. Sánchez‐Fueyo, Jane Tian, D. Picarella, C. Domenig, X. Zheng, C. A. Sabatos, Natasha Manlongat, O. Bender, T. Kamradt, V. Kuchroo and 3 more. Nature Immunology, 2003

741 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/8effa120dcb8de8853a553e5b0b5152747b1b408

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. D. Pardoll
2. S. Topalian
3. Charles G. Drake
4. A. Anderson
5. V. Kuchroo
6. D. Umetsu
7. S. Farkona
8. R. DeKruyff

In Molecular Biology

1. Eleftherios P. Diamandis
2. D. Pardoll
3. Andrew Emili
4. Jennifer Listgarten

Citations in the corpus

• Lag-3, Tim-3, and TIGIT co-inhibitory receptors with specialized functions in immune regulation (2016, background): “…with Tim-3-deficient mice and wild-type mice treated with Tim-3-Ig fusion protein showed that Tim-3 signaling is required for the induction of antigen-specific tolerance and that Tim-3 blockade enhances the development of spontaneous autoimmunity (Sabatos et al., 2003; Sánchez-Fueyo et al., 2003).”
• TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity (2010, background): “Moreover, administration of either TIM-3 Ig fusion protein or TIM3 mAb (8H7) to non-obese diabetic mice accelerated the onset of diabetes (68).”
• Immune checkpoint blockade: a common denominator approach to cancer therapy (2015, background): “TIM-3 knockout mice, similar to LAG-3 knockouts, do not develop overt autoimmunity (Sánchez-Fueyo et al., 2003), suggesting that TIM-3 and LAG-3 may have similarly subtle effects in modulating immune cell function.”
• Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients (2010, background): “In mice, blocking the Tim-3–Tim-3L pathway resulted in hyperproliferation of Th1-type cells and abrogated the induction of peripheral and transplantation tolerance (Sabatos et al., 2003; Sánchez-Fueyo et al., 2003).”
• Cancer immunotherapy: the beginning of the end of cancer? (2016, background): “Thus, for cancer vaccines to break the tolerance, high quantities of antigens must be targeted to DCs and these, in turn, need to be expanded and activated with appropriate agents [3].”